DE69625919T2 - Verwendung von zyklodextrine zur modulierten genexpression mit reduzierter immunostimulation - Google Patents
Verwendung von zyklodextrine zur modulierten genexpression mit reduzierter immunostimulation Download PDFInfo
- Publication number
- DE69625919T2 DE69625919T2 DE69625919T DE69625919T DE69625919T2 DE 69625919 T2 DE69625919 T2 DE 69625919T2 DE 69625919 T DE69625919 T DE 69625919T DE 69625919 T DE69625919 T DE 69625919T DE 69625919 T2 DE69625919 T2 DE 69625919T2
- Authority
- DE
- Germany
- Prior art keywords
- cyclodextrine
- gene expression
- reduced
- modulated gene
- reduced immunostimulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000003308 immunostimulating effect Effects 0.000 title abstract 3
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 2
- 230000014509 gene expression Effects 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/527,126 US6667293B1 (en) | 1995-09-12 | 1995-09-12 | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
| PCT/US1996/013311 WO1997010005A2 (fr) | 1995-09-12 | 1996-08-19 | Utilisation de cyclodextrines pour moduler l'expression genique, avec reponse immunostimulatrice reduite |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69625919D1 DE69625919D1 (de) | 2003-02-27 |
| DE69625919T2 true DE69625919T2 (de) | 2004-01-15 |
Family
ID=24100201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69625919T Expired - Lifetime DE69625919T2 (de) | 1995-09-12 | 1996-08-19 | Verwendung von zyklodextrine zur modulierten genexpression mit reduzierter immunostimulation |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6667293B1 (fr) |
| EP (1) | EP0850070B1 (fr) |
| JP (1) | JPH11512426A (fr) |
| AT (1) | ATE231398T1 (fr) |
| AU (1) | AU6848596A (fr) |
| CA (1) | CA2231687A1 (fr) |
| DE (1) | DE69625919T2 (fr) |
| DK (1) | DK0850070T3 (fr) |
| ES (1) | ES2187670T3 (fr) |
| WO (1) | WO1997010005A2 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6667293B1 (en) * | 1995-09-12 | 2003-12-23 | Hybridon, Inc. | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
| MXPA02001472A (es) * | 1999-08-10 | 2002-07-02 | Ml Lab Plc | Metodo para suministrar agentes terapeuticos utilizando una solucion de dextrina. |
| TWI321054B (en) | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
| US6624358B2 (en) * | 2001-12-13 | 2003-09-23 | Andrew Corporation | Miniature RF coaxial cable with corrugated outer conductor |
| PT1534340E (pt) | 2002-09-06 | 2012-03-13 | Cerulean Pharma Inc | Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente |
| JP4602085B2 (ja) * | 2002-10-09 | 2010-12-22 | セルリアン・ファーマ・インコーポレイテッド | シクロデキストリンを基材とした物質、組成物及びこれらと関連する用途 |
| US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| US8501740B2 (en) * | 2007-10-09 | 2013-08-06 | Board Of Regents, The University Of Texas System | Methods of treatment of opioid tolerance, physical dependence, pain and addiction with inhibitors of certain growth factor receptors |
| EP2600900A4 (fr) | 2010-08-06 | 2014-11-19 | Univ Illinois | Assemblages supramoléculaires multiplexes pour administration non virale de matériel génétique |
| US20140094432A1 (en) | 2012-10-02 | 2014-04-03 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
| US5068227A (en) * | 1989-01-18 | 1991-11-26 | Cyclex, Inc. | Cyclodextrins as carriers |
| US5149798A (en) | 1989-04-06 | 1992-09-22 | Worcester Foundation For Experimental Biology | Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses |
| US5248670A (en) | 1990-02-26 | 1993-09-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides for inhibiting herpesviruses |
| US5245022A (en) | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
| US5691316A (en) | 1994-06-01 | 1997-11-25 | Hybridon, Inc. | Cyclodextrin cellular delivery system for oligonucleotides |
| US6667293B1 (en) * | 1995-09-12 | 2003-12-23 | Hybridon, Inc. | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
-
1995
- 1995-09-12 US US08/527,126 patent/US6667293B1/en not_active Expired - Fee Related
-
1996
- 1996-08-19 DK DK96928899T patent/DK0850070T3/da active
- 1996-08-19 CA CA002231687A patent/CA2231687A1/fr not_active Abandoned
- 1996-08-19 WO PCT/US1996/013311 patent/WO1997010005A2/fr active IP Right Grant
- 1996-08-19 JP JP9511954A patent/JPH11512426A/ja not_active Ceased
- 1996-08-19 AT AT96928899T patent/ATE231398T1/de not_active IP Right Cessation
- 1996-08-19 AU AU68485/96A patent/AU6848596A/en not_active Abandoned
- 1996-08-19 ES ES96928899T patent/ES2187670T3/es not_active Expired - Lifetime
- 1996-08-19 DE DE69625919T patent/DE69625919T2/de not_active Expired - Lifetime
- 1996-08-19 EP EP96928899A patent/EP0850070B1/fr not_active Expired - Lifetime
-
2002
- 2002-10-23 US US10/278,429 patent/US20030148981A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997010005A3 (fr) | 1997-06-26 |
| DE69625919D1 (de) | 2003-02-27 |
| ES2187670T3 (es) | 2003-06-16 |
| DK0850070T3 (da) | 2003-04-22 |
| WO1997010005A2 (fr) | 1997-03-20 |
| AU6848596A (en) | 1997-04-01 |
| JPH11512426A (ja) | 1999-10-26 |
| EP0850070B1 (fr) | 2003-01-22 |
| US6667293B1 (en) | 2003-12-23 |
| ATE231398T1 (de) | 2003-02-15 |
| US20030148981A1 (en) | 2003-08-07 |
| EP0850070A2 (fr) | 1998-07-01 |
| CA2231687A1 (fr) | 1997-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69604686D1 (de) | Methode zur modulation der genexpression mit reduzierter immunstimulierender wirkung | |
| DE69720481D1 (de) | Verfahren zur verwendung von oligonukleotiden mit modifizierten cpg dinukleosiden | |
| GR3020557T3 (en) | Oligonucleotide alkylphosphonates and alkylphosphonothioates. | |
| DE69625919D1 (de) | Verwendung von zyklodextrine zur modulierten genexpression mit reduzierter immunostimulation | |
| EP0831848A4 (fr) | Procede de traitement de maladies pulmonaires au moyen d'oligonucleotides antisens | |
| NO965080D0 (no) | Antisens oligonukleotidmodulering av genekspresjon | |
| BR0011000A (pt) | Métodos para prevenir ou tratar uma doença associada com depósitos amilóides de ab no cérebro de um paciente, para avaliar um anticorpo quanto á atividade de remoção de uma entidade biológica fisicamente associada com um antìgeno e para detectara um depósito amilóide em um paciente, composição farmacêutica, e, conjunto de diagnóstico | |
| CA2229811A1 (fr) | Oligonucleotides chimeres et hybrides inverses | |
| ATE216705T1 (de) | Antisense-oligonukleotidmodulation der raf- genexpression | |
| EP1325019A4 (fr) | Modulation antisens de l'expression de la clusterine | |
| NZ504026A (en) | Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C | |
| EP1310555A3 (fr) | Modulation par oligonucleotide de la protéine kinase C | |
| EP1123414A4 (fr) | Modulation antisens de l'expression de l'integrine alpha 4 | |
| EP1430072A4 (fr) | Modulation antisens de l'expression de la proteine de transfert de l'ester de cholesteryle | |
| EP1250347A4 (fr) | Modulation antisens de l'expression de akt-3 | |
| PT1237562E (pt) | Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas | |
| EP1185696A4 (fr) | Modulation oligonucleotidique antisens de l'expression de la proteine kinase c-delta humaine | |
| EP1173458A4 (fr) | Modulation antisens de l'expression de sra | |
| Li et al. | Static magnetic field combined with functional appliances: A new approach to enhance mandibular growth in Class II malocclusion | |
| ATE302605T1 (de) | Tazaroten und uvb-phototherapie zur behandlung von psoriasis | |
| EA200001091A1 (ru) | Способ лечения заболеваний, связанных с образованием конкрементов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |